A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will investigate the efficacy and safety of Bonviva (150mg po monthly) in
the prevention of glucocorticoid-induced osteoporosis in post-menopausal women. Patients will
be randomized to receive either Bonviva 150mg po or placebo monthly, with vitamin D and
calcium supplementation. The anticipated time on study treatment is 1-2 years, and the target
sample size is 100-500 individuals.